Bevacizumab in stage II-III colon cancer: five year update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial. J Surg Oncol 2013; 31: 359-364.

Published: 12th December 2013

Authors: Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Lopa SH et al. et al.

Conclusion

In this study that included 2673 patients, the addition of bevacizumab to FOLFOX6 for twelve months did not improve disease-free (hazard ratio 0.93, 95 per cent confidence interval 0.81 to 1.08, P=0.35) or overall survival (0.95, 0.79 to 1.13, P=0.99) after median follow-up of five years.

Pubmed Link

Your comments

0 Comments